Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Common anti-seizure drug could be effective for lupus patients

17.11.2005


A common anti-seizure drug may be effective against certain conditions associated with lupus, according to animal research at Wake Forest University School of Medicine.



The drug, valproic acid (Depakote), prevents skin disease and reduces the severity of kidney disease in a mouse model of lupus, said Nilamadhab Mishra, M.D., a rheumatologist at Wake Forest University Baptist Medical Center.

"Valproic acid may be a potential cost-effective disease-modifying agent in lupus," Mishra reported today (Nov. 16) at the American College of Rheumatology meeting in San Diego.


And because the drug has been on the market since 1983, Mishra said that clinical trials to use valproic acid for lupus could begin as early as next year.

"We already know the side effects," he said. That means that researchers can skip over the safety studies and move quickly to clinical trials to test its efficacy. While physicians could prescribe valproic acid "off-label" to lupus patients, "it is better to have a clinical trial to prove that it does help in lupus," Mishra said.

Systemic lupus affects more than 1 million Americans, mostly women. About half of human patients with systemic lupus have kidney problems, but achy joints, skin lesions, frequent fever, arthritis and prolonged or extreme fatigue are far more common.

Mishra’s team tested valproic acid in a type of mouse that develops lupus that is similar to the lupus that occurs in people. None of the mice in the treatment group developed skin disease whereas all mice in the placebo group developed the disease, Mishra said. The results were similar for kidney and diseases of the spleen.

For instance, the spleen ordinarily enlarges in lupus. The size of the spleen in the treatment group was nearly one-third less than the size in the control group.

The study, which was paid for by a $250,000 grant from the Alliance for Lupus Research, was just one of several that Mishra presented at the national meeting,

In a second study, he showed that mithramycin, an antibiotic usually used against tumors, also reduces kidney disease in experimental mice with lupus.

Excess protein in the urine – proteinuria – is a symptom of kidney disease, Mishra said. In this study of mice born with lupus, only 33 percent of the mice getting mithrmycin had excess protein in the urine at 16 weeks, compared to 50 percent of the mice that were not treated. By 19 weeks, the gap had widened, with just 22.2 percent of the mithramycin group having excess protein, compared to 60 percent of the untreated group.

Other kidney function measures also showed a wide difference between the mithramycin group and the control mice. Renal vasculitis – inflammation of the tiny blood vessels in the kidney that can lead to kidney failure – occurred in 90 percent of the untreated mice, compared to 30 percent of the mithramycin group.

Mishra said that mithramycin might have a beneficial effect in people with lupus. "Further studies are warranted," he said.

At the same meeting, Mishra also described additional results from his ongoing research using a drug called TSA (Trichostatin A) on lupus. He described testing TSA on a second variety of mice that develop an autoimmune disorder similar to human systemic lupus.

In 2003, he had reported that in the same mouse model he used in the valproic acid and mithramycin studies, TSA led to a significant reduction in excess protein in the urine, inflammation of the kidneys, and spleen weight.

The new study, done in New Zealand Black and New Zealand White mice – which also develop an autoimmune disorder similar to lupus – had similar results.

Lupus is known as an autoimmune disorder because the body’s own immune system turns on the rest of the body and attacks tissues and organs including the joints, kidneys, heart, lungs, brain and blood.

Robert Conn | EurekAlert!
Further information:
http://www.wfubmc.edu

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>